JP7210540B2 - 血漿カリクレインの阻害剤およびその使用 - Google Patents

血漿カリクレインの阻害剤およびその使用 Download PDF

Info

Publication number
JP7210540B2
JP7210540B2 JP2020505842A JP2020505842A JP7210540B2 JP 7210540 B2 JP7210540 B2 JP 7210540B2 JP 2020505842 A JP2020505842 A JP 2020505842A JP 2020505842 A JP2020505842 A JP 2020505842A JP 7210540 B2 JP7210540 B2 JP 7210540B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
unsubstituted
amino
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529998A5 (https=
JP2020529998A (ja
Inventor
トラヴィンス，ジェレミー
ミラー，トーマス
パパイオアヌー，ニコラオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020529998A publication Critical patent/JP2020529998A/ja
Publication of JP2020529998A5 publication Critical patent/JP2020529998A5/ja
Priority to JP2023002547A priority Critical patent/JP7427812B2/ja
Application granted granted Critical
Publication of JP7210540B2 publication Critical patent/JP7210540B2/ja
Priority to JP2024008397A priority patent/JP7785108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020505842A 2017-08-04 2018-08-03 血漿カリクレインの阻害剤およびその使用 Active JP7210540B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023002547A JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用
JP2024008397A JP7785108B2 (ja) 2017-08-04 2024-01-24 血漿カリクレインの阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541403P 2017-08-04 2017-08-04
US62/541,403 2017-08-04
PCT/US2018/045183 WO2019028362A1 (en) 2017-08-04 2018-08-03 INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023002547A Division JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020529998A JP2020529998A (ja) 2020-10-15
JP2020529998A5 JP2020529998A5 (https=) 2021-08-26
JP7210540B2 true JP7210540B2 (ja) 2023-01-23

Family

ID=63209746

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505842A Active JP7210540B2 (ja) 2017-08-04 2018-08-03 血漿カリクレインの阻害剤およびその使用
JP2023002547A Active JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用
JP2024008397A Active JP7785108B2 (ja) 2017-08-04 2024-01-24 血漿カリクレインの阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023002547A Active JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用
JP2024008397A Active JP7785108B2 (ja) 2017-08-04 2024-01-24 血漿カリクレインの阻害剤およびその使用

Country Status (5)

Country Link
US (3) US11168083B2 (https=)
EP (2) EP4494698A3 (https=)
JP (3) JP7210540B2 (https=)
AU (3) AU2018311976B2 (https=)
WO (1) WO2019028362A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
KR20200143376A (ko) * 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) * 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
JP2025531207A (ja) * 2022-09-15 2025-09-19 武田薬品工業株式会社 遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのｎ－（（イソキノリン－６イル）メチル）－１ｈ－ピラゾール－４－カルボキサミド誘導体
CN116063215A (zh) * 2023-02-23 2023-05-05 南京安淮创新药物研究院有限公司 一种4-氨基-l-脯氨酸的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138532A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2017059178A1 (en) 2015-10-01 2017-04-06 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010083081A (ko) 1998-06-30 2001-08-31 실버스타인 아써 에이. 염증성질환, 자가면역질환 및 호흡기질환을 치료하는데유용한 브이엘에이-4-의존성 세포 결합의 비-펩티딜 억제제
UA96283C2 (uk) * 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2817291A1 (en) * 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
BR112017020864A2 (en) * 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
WO2017001936A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
KR20200143376A (ko) * 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
EP4031547B1 (en) * 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
CN114667289B (zh) * 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
PT4136091T (pt) * 2020-04-17 2025-08-22 Takeda Pharmaceuticals Co Formas e composições de inibidores da calicreína plasmática

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138532A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2017059178A1 (en) 2015-10-01 2017-04-06 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARDELLI, C. et al.，Discovery and Synthesis of HIV Integrase Inhibitors: Development of Potent and Orally Bioavailable N-Methyl Pyrimidones，Journal of Medicinal Chemistry，2007年，Vol.50, No.20，pp.4953-4975

Also Published As

Publication number Publication date
US20240199602A1 (en) 2024-06-20
AU2025204840A1 (en) 2025-07-17
JP7785108B2 (ja) 2025-12-12
WO2019028362A1 (en) 2019-02-07
JP2023040213A (ja) 2023-03-22
JP7427812B2 (ja) 2024-02-05
EP4494698A3 (en) 2025-04-23
US20220056028A1 (en) 2022-02-24
AU2023200156A1 (en) 2023-02-09
AU2023200156B2 (en) 2025-04-24
AU2018311976B2 (en) 2022-10-13
CA3070717A1 (en) 2019-02-07
US11168083B2 (en) 2021-11-09
AU2018311976A1 (en) 2020-02-06
US11905285B2 (en) 2024-02-20
JP2020529998A (ja) 2020-10-15
EP4494698A2 (en) 2025-01-22
EP3661922A1 (en) 2020-06-10
US20200239463A1 (en) 2020-07-30
JP2024045291A (ja) 2024-04-02
EP3661922B1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP7427812B2 (ja) 血漿カリクレインの阻害剤およびその使用
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
EP3652329B1 (en) Compounds for tau protein degradation
JP7097880B2 (ja) Ｍａｌｔ１分解のための化合物
JP7142022B2 (ja) Ｍａｌｔ１の阻害剤およびそれらの使用
CN105073768A (zh) Ras抑制剂及其用途
JP2025098013A (ja) がん幹細胞を標的化するがん治療
TW202434561A (zh) Ripk2抑制劑及其用途
KR20220110744A (ko) 암 줄기 세포를 표적화하는 암 치료
JP2024529487A (ja) Ｒｏｃｋ２阻害剤およびその使用
JP7185631B2 (ja) 抗線維化化合物
JP2024517789A (ja) グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
HK40123072A (en) Inhibitors of plasma kallikrein and uses thereof
CA3070717C (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252B (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252A (en) Inhibitors of plasma kallikrein and uses thereof
EA052549B1 (ru) Ингибиторы rock2 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230111

R150 Certificate of patent or registration of utility model

Ref document number: 7210540

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150